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1. Introduction 
South Africa is home to the world’s largest population of people living with HIV/AIDs (5.7 
million) and Sub-Saharan Africa is heavily affected with 22.4 million people living with the 
disease. Access to highly active antiretroviral (ARV) drugs is limited and many patients 
even when they are on ARVs consult traditional healers for herbal remedies. These 
traditional remedies as well as natural health products are widely used by HIV-infected 
patients in Southern Africa and other parts of the world. 
The limitations and uncertainties surrounding the effectiveness of ARVs in the treatment of 
HIV/AIDS have created a continuing search for new data on the possible drug-drug and 
drug-nutrient interactions. In this regard advances in the study of cytochrome P450, the 
enzyme system most commonly involved in drug metabolism, has provided mechanisms to 
investigate interactions of ARVs with natural health products and with nutrients in foods.  
This chapter reviews some of the possible effects of certain foods of plant origin, including 
dietary supplements of herbal and botanical origin, indigenous foods and traditional 
medicines on the regulation of CYP450 enzyme activities, focusing on their possible 
interaction with ARV drugs. It also discusses future considerations surrounding the 
improvement of HIV/AIDS treatment management aiming at reducing resistance to ARV 
drugs and increase awareness of potential food-drug interactions that can render ARV 
treatment ineffective.  
2. CYP450, ARVs and nutrition 
The cytochrome P450 enzymes are the major catalysts in drug metabolism and one of the 
best characterized metabolic protein complexes (Wilkinson, 2005). Although in humans 57 
CYP450 genes have been identified only a small number of the encoded proteins, mainly in 
the CYP1, CYP2 and CYP3 families, appear to contribute to the metabolism of clinically used 
drugs. CYP450 enzymes reduce or alter the pharmacologic activity of many drugs, 
attenuating its biological activity and facilitating or even accelerating its elimination from 
the body.  They can also metabolize many chemicals present in the diet and in the 
environment (Wilkinson, 2005). The major site of CYP450 mediated metabolism is the liver 
but the enterocytes in the epithelium of the small intestine is also a potentially important 
site. The gastrointestinal track is the site where insoluble ‘food/herb/natural products – 
drug complexes’ can be formed that can result in reduced drug efficacy.  
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2.1 Antiretrovirals (ARVs) 
The HIV virus uses three viral enzymes to replicate namely reverse transcriptase, protease 
and integrase. The current antiretroviral (ARV) drugs target the viral reverse transcriptase 
and the protease enzymes and are divided into four classes, nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and HIV 
protease inhibitors (PIs); the fourth class of ARVs are the HIV fusion inhibitors that prevent 
virus-cell fusion and this way prevents infection of target cells (Cos et al., 2004). Some of the 
anti-HIV drugs that are in clinical use are shown in Table 1. Normally a cocktail is prepared 
by combining two nucleoside reverse transcriptase inhibitors with either one non-
nucleoside transcriptase inhibitor or with one protease inhibitor in order to make a highly 
active ARV treatment (HAART) that has resulted in dramatic reductions of plasma virus 
levels (Anabwani & Navario, 2005). These ARV drugs are predominantly metabolized by 
the CYP450 enzymes in families CYP3A, 4, 5 and 7; the HIV protease inhibitors are also 
substrates for the drug transporter P-glycoprotein. 
The activity of CYP3A may be inhibited/reduced or induced as a result of drug interactions 
and this may have serious clinical implications. To try and minimize the problem of drug 
interactions, the identification and classification of many of the CYP3A substrates including 
the inhibitors and inducers of major clinical importance are available to clinicians so that an 
appropriate dosage strategy is found for each drug (Wilkinson, 2005). Rifampicin, a 
common drug used to treat tuberculosis, and some anticonvulsants are examples of drugs 
that induce CYP3A; so when these drugs are taken concurrently with HIV-protease 
inhibitors, therapeutic failure may occur as there is a marked reduction of the drug in the 
plasma. A similar situation can occur with non-prescription products like St John’s wort, 
used in alternative medicine, and a potent inducer of CYP3A (Wilkinson, 2005). In addition 
drug toxicity can also happen as a result of overlapping toxicities from drugs used to treat 
opportunistic infections and ARVs (Anabwani & Navario, 2005) as well as from drugs or 
traditional herbal medicines used to treat disorders associated with HIV-related problems 
like nausea, depression, insomnia, dermatological disorders, weakness and opportunistic 
infections (Mills, 2005b). 
There are however instances where the inhibitory effect to CYP3A activity from a drug can 
be used for therapeutic advantage. This is the case of the ARV protease inhibitor, ritonavir, 
which is known to “significantly reduce CYP3A-mediated first-pass metabolism of certain 
inhibitors of HIV-encoded protease and substantially increases their levels in the plasma” 
(Wilkinson, 2005).  This phenomenon has formed the basis of combining ritonavir with other 
protease inhibitors in the treatment of HIV-1 infection.   
2.2 Traditional remedies and herbal medicines 
Traditional medicines make use of the therapeutic power of plants and herbs and are widely 
used in Africa and in South Africa by traditional practitioners/healers, offering an 
alternative choice for the treatment of a variety of ailments and diseases. Some of the natural 
products and herbs that are used in traditional medicine are shown in Table2; some of their 
most common applications are also indicated. 
Plant extracts known to have antimicrobial properties have been found to be synergistic 
enhancers when taken in combination with standard drugs. In some cases the synergistic 
properties were only found to be effective when plant antimicrobials were taken 
concurrently with standard drugs, enhancing the effect of the drug.  Kamatou et al., (2006) 
reported on the effectiveness of two plants, Salvia chamelaeagnea and Leonotis leonurus against 
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Nucleoside reverse transcriptase inhibitors (NRTIs) 
Generic name Trade names 
Availability in 
South Africa 
Regimen in South Africa 
Didanosine 
Videx, ddl, Sspen-
Didanosine 
Yes 
Paediatric HIV infection 
regimen 2 
Adult HIV infection regimen 2 
Emtricitabine Emtriva, FTC No Not available 
Lamivudine 
Epivir, 3TC, Cipla-
Lamivudine, 
Aspen-Lamivudine
Yes 
Paediatric HIV infection 
regimen 1 
Adult HIV infection regimen 1 
Stavudine 
Zerit, d4T, Stavir, 
Aspen-Stavudine 
Yes 
Paediatric HIV infection 
regimen 1 
Adult HIV infection regimen 1 
Zalcitabine Hivid, ddC Yes 
Not currently part of SA 
guidelines 
Zidovudine 
Retrovir, AZT, 
ZDV,Aspen-
Zidovudine 
Yes 
Paediatric HIV infection 
regimen 2 
Adult HIV infection regimen 2 
Abacavir Ziagen Yes 
Adult and paediatric HIV 
infection 
Used in combination with other 
NRTIs 
Tenofovir Viread Yes No guidelines available 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
Generic name Trade names 
Availability in 
South Africa 
Regimen in South Africa 
Delavirdine Rescriptor Yes Not frequently used 
Nevirapine Viramune Yes Adult HIV infection regimen 1 
Efavirenz Sustiva, Stocrin Yes 
Paediatric HIV infection 
regimen 1 
Adult HIV infection regimen 1 
Protease inhibitors (PIs) 
Generic name Trade names 
Availability in 
South Africa 
Regimen in South Africa 
Indinavir Crixivan Yes No guidelines available 
Nelfinavir Viracept Yes No guidelines available 
Ritonavir Norvir Yes No guidelines available 
Saquinavir 
Invirase is a hard-
gel capsule; 
Fortovase is a soft-
gel capsule
Yes No guidelines available 
Amprenavir Agenerase Yes No guidelines available 
Atazanavir Reyataz Yes No guidelines available 
Fosamprenavir 
calcium 
Lexiva Yes No guidelines available 
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Fusion inhibitors 
Generic name Trade names 
Availability in 
South Africa 
Regimen in South Africa 
Enfuvirtide Fuzeon, T-20 No Not available 
Combinations of NRTIs, NNRTIs and PIs
Combinations Trade names 
Availability in 
South Africa 
Regimen in South Africa 
Combination of NRTI
Abacavir + 
Lamivudine 
Yes No guidelines available 
Combination of NRTI 
(Combivir, Avacomb, 
Aspen-Lamzid) 
Zidovudine + 
Lamivudine 
Yes No guidelines available 
Combination of NRTI
Abacavir + 
Zidovudine 
Yes (less 
common) 
No guidelines available 
Combination of NRTI
Didanosine + 
Zidovudine 
Yes (less 
common) 
No guidelines available 
Combination of NRTI
Stavudine + 
Lamivudine 
Yes (less 
common) 
No guidelines available 
Combination NRTI + 
NNRTI 
Tenofovir + 
Lamivudine + 
Efavirenz 
Yes 
Adult HIV infection 1st line 
regimen 1 
Combination NRTI + 
NNRTI 
Tenofovir + 
Lamivudine + 
Nevirapine 
Yes 
Adult HIV infection 1st line 
regimen 2 
Combination NRTI + 
NNRTI 
Stavudine + 
Lamivudine + 
Efavirenz 
Yes 
Adult HIV infection 1st line 
regimen 3 
Combination NRTI + 
NNRTI 
Stavudine + 
Lamivudine + 
Nevirapine 
Yes 
Adult HIV infection 1st line 
regimen 4 
Combination NRTI + 
NNRTI 
Zidovudine + 
Lamivudine + 
Efavirenz 
Yes 
Adult HIV infection 1st line 
regimen 5 
Combination NRTI + 
NNRTI 
Zidovudine + 
Lamivudine + 
Nevirapine 
Yes 
Adult HIV infection 1st line 
regimen 6 
Combination of PIs 
(Kaletra, LPV/r) 
Lopinavir + 
Ritonavir 
Yes 
Paediatric HIV infection 
regimen 1 
Adult HIV infection regimen 2 
Table 1. List of some of the anti-HIV drugs belonging to the four classes of ARVs in clinical 
use (Cos et al., 2004). The information relating to the drug availability and regimen in South 
Africa is from the South African Department of Health 
(www.doh.gov.za/docs/misc./hiv/manual/pharmacoloy_art.pdf) 
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Gram +ve bacteria when taken in combination than when they were taken individually.  
Aiyegon & Okoho (2009) reviewed the use of several bioactive plant products in 
combination with standard antibiotics demonstrating its application in antimicrobial 
chemotherapy. However they also cautioned on the possible problems related to toxicity 
and overdose as less concentration of the two products will be required when they are taken 
in combination. 
Information on the systems whereby bioactive plant products are metabolized is not readily 
available; future studies should be encouraged to ensure that better results can be obtained 
from the combined use of medicinal plants and the drugs used in orthodox medicine. It is 
necessary to understand what kind of interactions are possible and how best to avoid them 
so that that the maximum benefits are derived from the substances people ingest with the 
least possible risk.  
 
Plant 
Common 
name 
Applications and traditional uses References 
Allium 
sativum 
Garlic 
Anti-microbial and antispasmodic properties; 
antioxidant 
Mills & Bone, 
2000 
Aspalathus 
linearis 
Rooibos tea
 
Rooibos’ 
extracts 
Healthy drink; help with stomach cramp and 
vomiting in infantile colic; antioxidant 
Alleviate dermatological problems e.g. 
eczema, skin allergies 
Joubert et al., 
2008 
Athrixia 
phylicoides 
Bush tea 
Herbal tea; treatment of boils, acne, throat 
infections, infected wounds 
Joubert et al., 
2008 
Catharanthus 
roseus 
- 
Treatment of many disorders including 
diabetes, malaria, inflammation and 
hypertension 
van den Bout-
van den Beukel 
et al., 2006 
Cyclopia spp 
Honeybush 
tea 
Health booster; alleviate chronic catarrh and 
pulmonary tuberculosis 
Joubert et al., 
2008 
Harpagophytu
m procumbens 
Devil’s claw
Pain killer, improves flexibility and mobility 
associated with rheumatic diseases 
van den Bout-
van den Beukel 
et al., 2006 
Echinacea 
purpurea 
Echinacea /
Purple 
coneflower
Immune tonic; treatment of upper respiratory 
infections; anti-inflammatory 
Barret, 2003 
Hydrastis 
canadensis 
Goldenseal 
root 
Immune booster; antimicrobial ; anti-
inflamatory 
Sandhu et al., 
2003 
Hypoxis 
hemerocallidea 
African 
potato 
Antioxidant properties, treatment urinary 
infections, nervous disorders, cancer, HIV-
AIDS 
Mills et al., 
2005a 
Hypericum 
perforatum 
St. John’s 
wort 
Treatment of depression Lee et al., 2006 
Sutherlandia 
frutescens 
Cancer 
bush 
Anti-viral activity including retroviruses 
Anti-inflammatory properties 
Treatment of stress related maladies 
Mills et al., 
2005a 
Table 2. Some of the natural products and herbs used in traditional medicine with some of 
their most common applications 
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2.3 Nutrients in foods including indigenous foods and dietary supplements 
In addition to drug-drug interactions observed when drugs are metabolized by the same 
CYP450 enzyme system interactions between foods and drugs have also been reported and 
have been responsible for drug dosage adjustments in order to maintain drug 
concentrations within its therapeutic window (Jang et al., 2004).     
The various phases in which foods or dietary supplements may interact with co-
administered drugs are during gastrointestinal absorption, distribution, metabolism and 
elimination (Jang et al., 2004). The metabolic phase is particularly important in food-drug 
interactions where the consumption of particular foods modulates the activity of a drug-
metabolizing enzyme system, resulting in an alteration in the pharmacokinetics of the drugs 
metabolized by that system (Jang et al., 2004). Some foods and dietary supplements that 
contain complex mixtures of phyto-chemicals have the greatest potential to induce or inhibit 
the expression and activity of drug-metabolizing enzymes. 
The interaction between HIV/AIDS and nutrition is particularly important as severe 
malnutrition impairs immune function and decreases resistance to infection.  The immune 
cells depend on metabolic pathways that use various nutrients as critical cofactors for their 
actions and activities; during deficiencies of trace elements, of vitamins or when there is 
protein-calorie malnutrition, the individual defence mechanism is compromised. In 
developing countries micronutrient deficiencies are particularly common in HIV-infected 
individuals and several studies have shown that low serum levels of vitamin A poses a great 
risk for the rapid progression of the disease towards development of AIDS and then death 
(Anabwani et al., 2005).   
In order to address nutrient deficiencies in HIV-infected persons, particularly in developing 
countries, the consumption of a varied diet using foods high in nutritional value including 
protein, micronutrients and phytochemicals that are available in their communities has been 
encouraged. For the most vulnerable communities the available foods are primarily 
indigenous foods. There is very little known about the nutrient composition of some of the 
indigenous foods and about the interaction of the specific nutrients with ARVs. More efforts 
are being made to identify and analyse specific nutrients of indigenous foods in an attempt 
to increase awareness of potential food-drug interactions and maximize effectiveness of 
ARVs. 
Some of the traditional foods that are eaten in different parts of South Africa include 
pumpkin leaves with or without pumpkin seeds; amaranthus leaves; jugo beans; wild 
melon; bean mix made up of jugo beans, brown beans and maize; masonja made up of 
mopani and nuts; tihove made up of samp, nuts, cowpeas and beans; nyaka made up of 
wheat, sorghum, beans and peas; madumbe; corchorus; cleome and nightshade (T. Moroka, 
personal communication). In our laboratories we are in the process of evaluating plant food 
extracts from indigenous and traditional foods and remedies to determine the ability of 
these extracts to inhibit human CYP450 enzyme activities, especially CYP3A4, using  in vitro 
assays. This study will contribute to the evaluation of the impact that these foods can have 
in HIV-infected individuals if consumed at the same time as the ARV drugs are taken. 
2.4 Possible therapeutic failure or development of drug resistance  
Drug-drug interactions have become an important issue in health care where drug 
resistance or treatment failure is always a concern. As dietary and nutrient supplementation 
strategies are considered in the treatment of HIV infection it aims to take advantage of the 
mixture of active compounds derived from plant/herb extracts and ARVs to produce the 
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desired clinical effect. The same applies to the active ingredients in foods including 
indigenous foods; proper analysis should be done to determine the enzyme system by 
which these nutrients are metabolized and this way prevent any alteration in the 
pharmacokinetics of the ARVs. 
Clinical studies using drugs and herbal medicines with the same metabolic route as ARVs 
have shown to have the potential to significantly interact with ARV metabolism through the 
modulation of hemethiolate-containing enzymes of the CYP450 system, in particular 
CYP3A4 activity. Hypoxis hemerocallidea, commonly known as African potato, and 
Sutherlandia, are two botanical supplements widely used in Sub-Saharan Africa that have 
been reported to potentially increase drug toxicity, viral resistance and treatment failure 
when used in conjunction with ARVs (Mills et al., 2005a).  
The marked inhibitory effect of grapefruit juice with a number of orally administered drugs 
that are substrates to CYP3A4 was first reported by Bailey et al., (2003). Further 
investigations confirmed that due to its interaction with prescribed drugs where the peak of 
a drug level could be increased by a factor of three without any change in the half-life of the 
medication, grapefruit is contra-indicated in patients receiving drugs that are mainly 
metabolized by CYP3A4 (Jang et al., 2004).  There are many other reports where treatment is 
rendered ineffective because of unknown interactions between nutrients and prescribed 
drugs and it is particularly important when the total drug absorption is altered (Bibi, 2008). 
Drug toxicity also exists with drugs that are modulated by CYP1A2 when co-administered 
with CYP1A2 dietary supplements. Jan et al. (2004) reported a study done on patients taking 
certain drugs that are metabolized by CYP1A2 (acetaminophen, imipramine, theophylline, 
estradiol or warfarin). When these drugs were taken concurrently with CYP1A2 dietary 
supplements the patients’ ability to metabolize the drugs was considerably lowered and 
could have resulted in drug toxicity.  On the other hand when these drugs were taken 
concurrently with CYP1A2-inducing dietary supplements, the patients’ ability to metabolize 
the drugs was greater causing them to be eliminated faster, resulting in reduced 
pharmaceutical activity (Jang et al., 2004). However for the purpose of this short review 
emphasis was placed on reports of drug-food interactions with drugs and foods that are 
modulated by the same CYP450 enzyme systems used by the commonly used ARVs in 
Africa.  
A study of herb-drug interactions between five Malaysian medicinal plants and drugs 
metabolized by CYP2C9, CYP2D6 and CYP3A4 showed that Orthosiphon stamineus, 
Mitragyna speciosa and Andrographis paniculta were potential inhibitors of the three enzyme 
activities, suggesting that these medicinal plants should not be used simultaneously with 
these classes of drugs (Hanapi et al., 2010). Two other plants Eurycoma longifolia and 
Mitragyna speciosa showed no significant inhibition suggesting that they can be taken 
concurrently with ARVs. These tests were done using an in vitro assay system that contains 
recombinant human CYP450 enzyme; this is the same in vitro system that is being used in 
our laboratories as it is sufficiently robust to handle many samples at the same time (E. 
Barros, personal communication). 
Rooibos (Aspalathis linearis) tea and honeybush (Cyclopia intermedia) tea are natural herbs 
indigenous to South Africa that have been widely used as herbal remedies for a wide range 
of ailments. The antioxidant properties of the teas and plant extracts from these two plants 
are important in boosting the human immune system; these antioxidants protect cells 
against oxidative damage by scavenging for free radicals. However the simultaneous intake 
of rooibos and honeybush with certain ARV drugs should be taken with caution due to the  
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Plant/herb 
name 
Test 
system
Relevant chemical 
constituents (bioactive)
Effect on CYP3A4 
enzyme system or P-gp
References 
American 
Ginseng 
(Panax 
quinquefolius) 
In vitro
Ginsenoside, 
propanaxatriol 
ginsenoside 
Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Asian 
Ginseng 
(Panax 
ginseng) 
In vitro
Ginsenoside, 
propanaxatriol 
ginsenoside 
Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
African 
potato 
(Hypoxis 
hemerocallidea) 
In vitro
Hypoxoside which is 
converted into rooperol
Increase inhibition by 
86% CYP3A4 
Mills et al., 
2005a, 2005b 
Catharanthus 
roseus 
In vitro
Ajmalicine and 
serpentine 
Weak or no inhibitory 
effect CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Seville orange 
(Citrus 
aurantium) 
In vivo
In vitro
- 
- 
Inhibition P-gp 
Inhibition CYP3A4 
Tarirai et al., 
2010 
Devil’s claw In vitro Harpagoside Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Echinacea In  vitro Quercetin Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Eucalyptus oil 
(Eucalyptus 
globules) 
In vitro Cineole Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Evening 
primrose 
In vitro
Linoleic acid, oleic acid, 
palmitic acid, stearic 
acid 
Moderate inhibition 
CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Garlic 
In vitro 
and In 
vivo 
Clinical 
studies
In vivo
Alliin, allicin 
 
Garlic extracts 
 
Garlic extracts 
Weak inhibition 
CYP3A4 
 
Induction CYP3A4 and 
P-gp 
 
No significant 
inhibition of CYP3A4 
Tarirai et al., 
2010 
 
Piscitelli et al., 
2002 
 
Markowitz et al., 
2003 
Ginger 
(Zingiber 
officinale) 
Case 
report
Gingerols, zingiberene, 
shoagols, 
Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Ginkgo 
(Ginkgo biloba) 
In vitro Ginkgolic acids 
Inhibition CYP3A4 and 
P-gp 
van den Bout-
van den Beukel 
et al., 2006 
www.intechopen.com
 
Interaction of Traditional Remedies Against HIV, Nutrients and ARVs 
 
119 
Goldenseal 
root 
(Hydrastis 
canadensis) 
In vitro
Clinical 
studies
Isoquinoline alkaloids 
Inhibition CYP3A4 
No effect on CYP3A4 
nor P-gp 
Sandhu et al., 
2003 
Lee et al., 2006 
Grapefruit 
juice 
(Citrus 
paradise) 
In vivo
 
In vitro 
and in 
vivo 
Naringenin; 
furanocoumarin 
bergamottin; 
Diosmin 
Inhibition CYP3A4
 
 
Induction CYP3A4 and 
P-gp 
Tarirai et al., 
2010 
Milk thistle 
(Silybum 
marianum) 
In vitro
Clinical 
studies
Isoprenoid 
dihydrosilybins, 
silymarin, sylibinins, 
taxifolin, 
apigenin,luteolin 
Induction P-gp 
Tarirai et al., 
2010 
van den Bout-
van den Beukel 
et al., 2006 
Rooibos tea In vivo Pinitol Induction CYP3A 
Matsuda et 
al.,2007 
Soy 
(Glyvine max) 
In vitro
Genistein, daidzen 
(phytoestrogen) 
Inhibition CYP3A4 and 
P-gp 
van den Bout-
van den Beukel 
et al., 2006 
St John’s wort In vitro
Hyperforin, hypericin, 
quercetin, isoquercetin, 
biflavonoids, 
naphthoadianthrones, 
catechins, tannins
Induction CYP3A4 and 
P-gp 
Piscitelli et 
al.,2000 
Mannel, 2004 
Sutherlandia In vitro
L-canavanine that is an 
arginine analogue 
Near complete 
inhibition (96%) 
CYP3A4 
Inhibition P-gp 
Mills et al., 2005a 
van den Bout-
van den Beukel 
et al., 2006 
Cranberry 
juice 
(Vaccinium 
macrocarpon) 
In vitro
Flavonoids 
(antioxidants) 
Inhibition CYP3A4 
van den Bout-
van den Beukel 
et al., 2006 
Valerian 
(Valeriana 
officinalis) 
In vitro
Isovalerianic or valerenic 
acid 
Inhibitor CYP3A4 and 
P-gp 
van den Bout-
van den Beukel 
et al., 2006 
Table 3. Examples of plant and herbal products used with ARVs in the treatment of HIV-
AIDs with reference to metabolism by CYP450 3A4 and/or P-glycoprotein (P-gp) 
induction of CYP3A4 activity (Mashuda et al., 2007); they should be taken preferably at 
different times. Table 3 contains some examples of plant and herbal products used with 
ARVs in the treatment of HIV-AIDs with reference to metabolism by CYP450 3A4 and/or P-
glycoprotein (P-gp). 
The concurrent use of natural health products with ARVs is also widespread and there are 
varied reports on the level of interaction with certain natural health products resulting in 
changes in the efficacy of the ARV treatment. Natural health products are often complex 
mixtures containing organic compounds many of which can induce and/or inhibit the 
enzymatic pathways involved in the metabolism of ARV drugs (Lee et al., 2006).  
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St. John’s wort, a well known natural health product, is commonly used by HIV-infected 
patients due to its antidepressant properties. One of its constituents, hyperforin, is a very 
active inducer of CYP3A4 activity and responsible for a reduction in drug activity. Mannel 
(2004) reported a case of a reduction in the activity of an ARV drug cocktail containing 
indinavir-lamivudine-stavudine when it was co-administered with St John’s wort. A similar 
interaction of St John’s wort was reported with the co-administration of two separate ARVs 
namely indinavir and nevirapine (Lee et al., 2006).  
Garlic is another natural health product commonly used by HIV-infected patients where 
reports have shown different types of interactions with different ARVs. A decrease in the 
plasma concentration of fortovase, the soft gel formulation of saquinavir, was found in 
patients taking garlic while on fortovase treatment possibly due to induction of intestinal 
CYP3A4 and/or P-gp (Piscitelli et al., 2002). Another report of the concurrent intake of garlic 
supplements by an HIV-infected patient on ritonavir therapy suggested inhibition of garlic 
metabolism caused by ritonavir leading to potential garlic toxicity (Lee et al., 2006). Other in 
vivo and in vitro studies on the pharmacokinetic interactions of garlic with ARVs have 
reported either a slight reduction or no effect on CYP3A4 activity. The variation observed 
with the co-administration of garlic and the different ARVs are possibly due to the different 
garlic constituents present in the various garlic supplements.  
Vitamins are another group of natural health products widely used by patients on ARV 
therapy. However evaluation of the pharmacokinetic interactions between vitamins and 
ARVs is very complex as not only there are many vitamins but there are also different 
combinations of vitamins, different doses and they can also be administered singly or in a 
multivitamin form. So vitamins tend to be evaluated singly. The two most commonly tested 
vitamins are Vitamin C and Vitamin E.  A study of the interaction between Vitamin C and 
indinavir   done on healthy people using a high dosage of Vitamin C (1000 mg/day) showed 
a reduction in the plasma concentration of indinavir. A variation was however observed in 
the level of bioavailable indinavir among the different individuals (Slain et al., 2005). This 
interaction would lead to treatment failure in HIV-infected individuals.  
Goldenseal root was reported to cause a strong inhibition in the activity of  CYP3A4  using 
in vitro studies (Lee et al., 2006), yet when clinical tests were done on the interaction between 
goldenseal and indinavir, no change was observed in the bioavailability of indinavir 
(Sandhu et al., 2003). 
It is important to note that there is some variation on the results obtained for the in vitro and in 
vivo evaluations of the pharmacokinetic interactions among natural health products and ARVs 
and those obtained from clinical studies. One possibility could be the pharmacogenetic 
influence on the clinical studies that is absent in both in vitro and in vivo studies.   
Although in most cases the pharmacokinetic interactions of ARVs with other products are 
done with a single ARV it is rare for an ARV therapy to include a single ARV; it normally 
contains combinations of two and most commonly three antiretroviral drugs. This makes 
the study of the interaction of these different combinations of ARV drugs with the different 
natural health products and complementary medicines a more complex task. It is however 
valuable to know the metabolic route of each natural health product and complementary 
medicine so that a better judgment can be made of what to take and when, to avoid 
treatment failure and worse still, to prevent the development of resistance to treatment by 
HIV-infected individuals. Tarirai et al. (2010) suggested that certain NHPs and 
complementary medicines could be administered either 2 hours before or 2 hours after the 
drug for which an interaction is known to exist. 
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There are some reports on the beneficial interaction between some natural health products in 
helping to reduce the progression of HIV/AIDS either by targeting the HIV virus replication 
or by alleviating the toxic effects associated with the intake of ARVs; more scientific and 
clinical data is however still needed. Antioxidants play an important part in maintaining a 
healthy immune system and controlling oxidative stress.  The presence of oxidative stress in 
HIV-infected individuals is known to contribute to the progression of the disease. Although 
the role of plant-derived antioxidants including flavanoids and proanthocyanins in helping to 
reduce oxidative stress has been suggested in HIV-infected individuals there is not enough 
evidence to confirm this to be the case (Cos et al., 2004). While a dietary intervention with 
antioxidants could be considered as a cost-effective strategy in the HIV treatment the 
metabolic route of these plant derived antioxidant compounds need to be properly evaluated 
to prevent any pharmacokinetic interactions with ARV drugs.  
While limited information is available on the pharmacokinetic interactions between natural 
health products and other complementary and alternative medicines with ARV drugs often 
healthcare providers and patients perceive their concurrent administration unlikely to be 
harmful. In addition physicians are often not aware of the patients’ use of natural health 
products or complementary medicines and are therefore not able to discuss with the patient 
the best way to combine the use of conventional medicine with unconventional therapies, 
including herbal medicines. 
An aspect that is particularly important in developing countries, where the level of 
malnutrition is very high, is the possible effect that fortified staple foods can have on HIV-
infected individuals by the simultaneous intake of ARVs. A similar situation has been 
reported with the co-administration of certain antibiotics, like tetracyclines and 
fluoquinolones, which bind to the iron and calcium in foods and in dietary supplements 
(Tarirai et al., 2010). Awareness should also be made with the concurrent intake of certain 
fortified foods. Tuntipopipat et al. (2006) reported a reduction in the absorption of iron by a 
group of healthy females that consumed iron-fortified foods together with Chilli pepper. 
The iron was bound to capsaicin, the polyphenos that are found in Chilli (Capsicum annum). 
To avoid these types of interactions the intake of certain herbal preparations should be 
administered a couple of hours before or after the interacting drug. This approach will 
prevent the development of drug resistance that can be the result of reduced clinical efficacy 
of the drug. 
In South Africa food fortification programmes have been implemented especially in schools 
in order to overcome some of the nutrient deficiencies including micronutrient deficiencies 
linked to poverty and malnutrition. These deficiencies are being addressed by the 
mandatory fortification of table salt with iodine and maize meal and bread flour with a 
vitamin mixture and mineral mixture (Vorster, 2010). The pharmacokinetic evaluations of 
fortified foods need to be included in future research to prevent treatment failure or 
development of resistance by any HIV-infected individuals.   
2.5 Screening of natural health products and nutrients in foods for metabolism with 
CYP450 enzymes 
CYP450 enzymes are biocatalytic enzymes crucial for the metabolisms of drugs and toxins. 
The CYP450 system is genetically determined and as such it varies among people. The 
polymorphic forms of CYP450 genes are responsible for the development of a significant 
number of adverse drug reactions (Ingelman-Sundberg, 2004). This constitutes an additional 
challenge for health practitioners to achieve the optimum level of a drug. There are some 
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commercial tests available that can determine the individual’s CYP450 activity based on the 
analysis of a blood-derived DNA sample. This test is available for CYP2D6 and CYP2C19 
enzymes which cover about 25% of all drugs (Ingelman-Sundberg, 2004) but do not include 
CYP3A4, 5 and 7 enzyme families through which the currently used ARVs are metabolized. 
The pharmacogenetic profile of individuals on ARV treatment is an important factor in the 
evaluation of safety and risk of co-administered drugs with certain herbal/plant products; 
however this was outside the scope of this review.  
CYP450 analysis of herbal and plant natural products commercially available as natural 
health products or complementary medicines was reported by Strandell et al., (2004) 
using in vitro inhibition assays. Extracts were prepared from these products and the level 
of inhibition of CYP3A4, 2D6 and 2C19 enzyme activities identified.  Based on the levels 
of inhibition obtained for each of the products additional tests could be suggested 
including in vivo interaction studies. The screening of the active ingredients of 49 herbal 
species for the potential inhibition of CYP3A4 was reported by Lee et al., (2007) using a 
CYP HerboChip®. As these screening platforms become available it facilitates future 
research to determine the potential interactions between commonly used herbal 
medicines, natural foods and antiretroviral agents in order to prevent treatment failure 
and resistant HIV in HIV-infected individuals. 
2.6 The way forward  
Reliance on traditional herbal medicine by the majority of the population in Sub-Saharan 
Africa and the global increase in the use of natural products it will most probably contribute 
in an increase in the pharmacokinetic interactions between herbs and drugs; between 
natural ingredients found in foods, in natural health products or in complementary 
medicines and drugs; between drug and drug; and between herb and herb. As most of the 
herbs and natural products are categorized as foods it suggests that they did not have to 
follow the rigorous safety and efficacy regulations that are expected from prescription drugs 
including ARVs. 
Knowledge of the potential interactions between drugs, ARVs and plant derived products is 
very limited and more research needs to be done to identify potential harmful interactions. 
The information generated needs to be documented and made available to traditional 
healers, health practitioners and also to the HIV-infected individuals so that they can 
understand the impact that those interactions can have on the development of drug 
resistance and treatment failure.  
Caution should be exercised when evaluating the pharmacokinetic results of the plant 
extracts and herbal extracts since the extractions of the different constituents are not 
chemically standardized. Depending on the protocols used to extract the metabolic 
components of a particular plant a different result may be produced which in turn will 
generate a different outcome with the ARV drug concentrations. Moreover the same 
product that is available from a different ‘brand’ may produce a different result. While the 
production of drugs and other pharmaceutical agents have a defined chemical structure and 
molecular formula regardless of the manufacturer, there are many constituents in a 
particular plant extract. In addition their profiles are not only affected by the extraction 
method but can also be influenced by the plants' growing conditions, geographical location, 
part of the plant used, post-harvesting treatment and formulation among many other factors 
(Ngo et al., 2009). Although this process is very complex it should not deter from the 
implementation of a rigorous evaluation of the constituents in foods derived from plants so 
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that appropriate corrective steps can be taken to address the concerns of individuals taking 
certain ARV medications concomitantly with certain foods.  
The first step in the study of the pharmacokinetic interactions with ARV drugs should be to 
perform in vitro tests of the constituents of natural health products, complementary 
medicines, herbal products and indigenous foods. This approach allows the profiling of 
secondary metabolites of many natural products enabling the identification of any 
interactions in the modulation of CYP450 enzyme system before establishing the need to 
conduct more time-consuming and costly clinical studies. Furthermore the rigorous in vitro 
characterization of any dietary substance should be undertaken before embarking on a 
clinical drug-diet interaction study.  
The way forward is therefore to make the healthcare givers, doctors, nurses and school 
dietitians aware of the possible food-drug interactions that occur through the formation of 
insoluble complexes in the gastrointestinal tract that can reduce the bioavailability of the co-
administered ARV drugs.  
3. Conclusion 
Herbal medicines and other dietary supplements such as vitamins are commonly used as 
alternative medicines in Europe, America and Africa. In Africa herbal medicines are an 
integral part of the treatment regimen of most HIV-infected patients. However not enough 
information is available on the possible interactions between commonly used herbal 
medicines and antiretroviral agents. Furthermore many of the HIV-infected patients on 
antiretroviral therapy often do not report the concomitant usage of herbal medicines to their 
physicians; on the other hand not always the physicians are aware of the risk for herb-ARV 
interactions and therefore do not discuss the simultaneous intake of herbal medications with 
ARVs with their patients. Greater awareness and education is required to show that when 
herbal medicines and ARVs are metabolized by the same CYP450 enzymes significant drug 
interactions can occur. Those interactions can result in either induction or inhibition of the 
CYP450 enzymes that are involved in ARV metabolism. While induction could lead to 
subtherapeutic plasma levels of the ARV leading to possible therapeutic failure and 
enhanced risk of developing ARV drug resistance, inhibition could lead to high ARV plasma 
levels with the risk of possible serious side effects.  
A contribution to the HIV-infected persons in developing countries is to continue to 
determine the CYP enzyme system used by the foods and remedies that they consume and 
this way try to reach an optimal plasma level of the ARVs in HIV-infected individuals. 
Although in vitro evaluations of the potential interactions of plant extracts from foods and 
herbs have been reported this represents only a small fraction of what is used by the 
different population groups in Africa including South Africa. The work that we have 
initiated covers a selection of indigenous foods and traditional medicines consumed by the 
resource poor communities in the region and it will contribute towards increased awareness 
of potential food-drug interactions;  if the foods tested are found to be substrates for 
CYP450, especially CYP3A4,  the potential interaction with some of the ARVs can be 
anticipated and the appropriate adjustments made to the ARV treatment; it will lead to a 
more effective ARV treatment and it will improve the quality of life of the people living with 
HIV/AIDS. Furthermore the knowledge being generated in this and similar studies will 
help prevent the development of drug resistance by people on HIV-treatment through the 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
124 
consumption of foods and food-related products that are modulated by the same CYP450 
system of the ARVs. 
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